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Introduction:Acute arterial thrombosis causes endothelial dysfunction due to decreased nitric oxide bioactivity. Increased
arginase activity may modulate intracellular L-arginine levels, the substrate for nitric oxide. The purpose of this study was
to identify the role of arginase in endothelial dysfunction in cell culture and in the vasomotor response of arteries exposed
to thrombus.
Methods: Rat aortic endothelial cells were exposed to thrombin at different time points. The cell extract was analyzed by
immunoblotting and real-time polymerase chain reaction. Adult male rats underwent infrarenal aortic thrombosis by clip
ligature for 1 hour. Infrarenal aortic ring segments were harvested and placed in physiologic buffer baths, and a force
transducer was used to measure endothelial-dependent relaxation (EDR) and endothelial-independent relaxation (EIR).
Arginase blockade was performed by incubating infrarenal aortic ring segments with arginase inhibitors for 1 hour before
measuring EDR. Whole tissue extracts also underwent immunoblot analysis. The EDR and EIR curves were compared
with analyses of variance.
Results: A 6.76  1.4-fold induction in arginase I message levels (P  .001) was found in rat aortic endothelial cells
exposed to thrombin (30 U/mL), and arginase I protein levels increased 2.1 times. The eight infrarenal aortic ring
segments exposed to thrombosis for 1 hour had diminished EDR curves compared with 14 nonthrombosed normal
segments (controls). The maximum ( SEM) EDR (acetylcholine 105M dose) in control infrarenal aortic ring segments
was 108%  4.3% compared with 63%  6.2% for thrombosed infrarenal aortic ring segments (P < .001). Exposure to
arterial thrombosis resulted in a 3.8-times increase in arginase I protein levels in infrarenal aortic ring segments.
Preincubation of nine infrarenal aortic ring segments with the nonspecific (difluoromethylornithine) and six with specific
([S]-[2-boronoethyl]-L-Cysteine-HCl [BEC]) arginase inhibitor for 1 hour significantly increased the maximum EDR
compared with untreated thrombosed segments (104  5.2, 108  7.6 vs 63%  6.2, P < .001). EDR curves for
difluoromethylornithine- and BEC-treated infrarenal aortic ring segments were superimposed on control EDR curves.
The EIR and the vasoconstriction with norepinephrine for all groups were similar.
Conclusion: Endothelial cells exposed to thrombin have increased arginase I messenger RNA and protein levels. Arterial
thrombosis causes endothelial dysfunction without affecting smooth muscle responsiveness. Arginase blockade can lead
to normalization of arterial vasomotor function. (J Vasc Surg 2008;48:441-6.)
Clinical relevance. Acute arterial thrombosis may lead to endothelial dysfunction, manifested clinically by vasospasm and
rethrombosis after initially successful thrombectomy or thrombolysis. We have identified that the key enzyme, arginase,
which modulates levels of the nitric oxide precursor, L-arginine, is increased in arterial thrombosis. Thrombin, a
component of thrombus, increases arginase levels, which may lead to decreased nitric oxide bioavailability. These studies
indicate that arginase blockade restores endothelial function in arteries exposed to thrombosis. This work may lead to
therapeutic alternatives including L-arginine supplementation or arginase blockade for patients with acute ischemia.Endothelial dysfunction, which is observed in various
vascular conditions,1-3 has been attributed to the decreased
nitric oxide (NO) production by endothelial NO synthase
(eNOS). In several of these conditions, supplementation of
L-arginine, the precursor of NO, has been shown to im-
prove NO production even though eNOS activity and
concentrations have been reported to be normal.4-7 This
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doi:10.1016/j.jvs.2008.02.030indicates that a functional lack of L-arginine contributes to
decreased NO levels and endothelial dysfunction.
These surprising findings have led to the recognition of
an “arginine paradox,” because normal intracellular con-
centrations of L-arginine should saturate the eNOS en-
zyme.8 The plausible explanations for this complex phe-
nomenon include compartmentalization of eNOS and its
substrate, alterations in L-arginine transport, or production
of an endogenous NOS inhibitor like asymmetric dimethy-
larginine, or both. Increased arginase activity as an etiology
for endothelial dysfunction is another possibility. Compe-
tition between eNOS and arginase for the substrate L-
arginine could lead to decreased NO production if the
balance shifted to L-arginine metabolism by arginase.
Arginase, an important enzyme of the urea cycle, is a
binuclear manganese metalloenzyme and hydrolyses L-
arginine to ornithine and urea. Of the two isomers, arginase
I is predominately expressed in the liver as a cytosolic
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endothelial cells. Arginase II is found in mitochondria and
expressed in extrahepatic tissues, including the kidney.
Arginase II is the predominant human isoform. Although
these two enzymes have diverse functions, both can mod-
ulate NO production.9
Arterial as well as venous thrombosis depresses the
ability of the vasculature to relax to various endothelial
dependent stimuli.6,7,10 In experimental models, this is
evidenced by depressed endothelial-dependent relaxation
(EDR), a measure of the endothelium’s ability to produce
NO after appropriate stimulation. A clinically relevant an-
alog is seen in patients with peripheral arterial thrombosis
and vasospasm that can prevent the successful restoration of
blood flow. From prior observations, we hypothesize that
increased arginase activity may contribute to the endothe-
lial dysfunction in arteries exposed to acute thrombus and
its major component, thrombin. In this study, we tested
this hypothesis using cell culture to explore themechanisms
involved and an animal model of arterial thrombosis.
MATERIAL AND METHODS
Cell culture. Rat aortic endothelial cells (RAEC) were
isolated and initially plated onto T75 flasks in a 37°, hu-
midified, 5% carbon dioxide incubator. They were main-
tained in Dulbecco Modified Eagle’s Medium (Sigma, St.
Louis, Mo) containing 15% fetal bovine serum, 0.009%
heparin, and 0.015% endothelial cell growth supplement.
The cells were grown to confluence before initiation of
experiments and were used between passages 3 and 5.
RAECs were rinsed in heparin-free media before exposure
to bovine thrombin.
Real-time polymerase chain reaction. Arginase I
messenger RNA (mRNA) expression was measured using
real-time polymerase chain reaction (RT-PCR) from non-
treated cells (control) and cells treated with thrombin (10
and 30 U/mL) for 1, 4, and 6 hours. Total RNA was
extracted from 2  106 RAECs using standard phenol-
chloroform extraction (Rneasy Mini Kit, Qiagen, Valencia,
Calif). The quantity of total RNA was determined by A260
absorbance. Complementary DNA production and ampli-
fication were synthesized from total RNA (1 g) isolated
from control and treatment cells using RT-PCR (Roche,
Indianapolis, Ind) according to the manufacturer’s instruc-
tions. Volume of the reaction mixture was made up to 25
L, and 5 L of this reaction mixture was used to perform
PCR with the following specific rat arginase I primer pairs:
Forward: 5=-GCCAATGAACAGCTGGCTGCTGT-3=;
Reverse: 5=-TACATCGGCTTGCGAGATGTGGA-3=.
RT-PCRwas performed using SYBR green PCR core reagent
and a Perkin-Elmer ABI PRISM7700 sequence detector (PE
Applied Biosystems, Foster City, Calif), according to the
manufacturer’s instructions. This quantification is expressed
as fold induction compared with controls.
Western blotting. Cellular lysates from RAECs and
whole tissue lysates from control and thrombosed infrare-
nal segments and were electrophoresed on a 12% sodiumdodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) gel. The gel was soaked in protein transfer buffer
(39mM glycine, 48mM Tris base, 0.037% SDS, 20% meth-
anol) for 20 minutes at room temperature and then trans-
ferred to nitrocellulose using a Trans-Blot semi-dry transfer
cell (Bio-Rad, Hercules, Calif). The blot was blocked with
5% bovine serum albumin (BSA). Next, the blot was incu-
bated with polyclonal antiarginase I (sc-18351) and II
(sc-20151) antibody (Santa Cruz Biotechnology, Santa
Cruz, Calif) in 5% BSA overnight at 4°C. The blot was
washed three times with Tris-buffered saline Tween-20
and incubated for 1 hour with goat antirabbit horseradish
peroxidase-conjugated secondary antibody (Jackson Im-
munoresearch, West Grove, Pa) at room temperature. Pro-
tein bands were detected using chemiluminescence.
Animals. Adult, male Sprague-Dawley rats weighing
350 to 500 mg were used for all experiments. Animals were
handled and cared for under Cleveland Clinic guidelines
and in compliance with the Guide for the Care and Use of
Laboratory Animals (Institute of Laboratory Animal Re-
sources, National Research Council, National Academy
Press, Washington, DC, 1996) and the American Associa-
tion for the Accreditation of Laboratory Animal Care
(AAALAC). The experimental protocols were approved by
the Cleveland Clinic Institutional Animal Care and Use
Committee and were performed in accordance with the
recommendations of Good Laboratory Practices.
Surgical procedures. Intraperitoneal injections of
ketamine (80 mg/kg) and xylazine (8 mg/kg) were used
for anesthesia. The aorta was ligated with small surgical
clips just distal to the renal arteries and proximal to the
bifurcation to induce arterial thrombosis, as previously
described.6 Aortic segments were harvested before any
intervention (controls), or after a prescribed time interval of
thrombosis. The presence of intraluminal thrombus was
confirmed in all animals at the time of tissue harvest.
Studies of endothelial and smooth muscle cell
function. The infrarenal aorta was carefully harvested,
placed in Krebs-Henseleit physiologic solution (118mM
NaCl, 25mM NaHCO3, 5.6mM glucose, 1.2mM
KH2PO4, 4.7mM KCL, 0.6mM MgSO4, 2.5mM CaCl2),
and sectioned into 4-mm segments. The segments were
mounted on standard tungsten wire triangles (A-M Sys-
tems, Everett, Wash), attached to isometric force displace-
ment transducers (Radnoti Systems Inc, Monrovia, Calif),
and placed into tissue baths. The tissue baths were temper-
ature controlled with a heated water jacket at 37°C. Stan-
dard Krebs-Henseleit solution was used with a gas mixture
of 95% oxygen and 5% carbon dioxide bubbled into the
baths.
Preload (2 g) was applied to the arterial rings, and the
vessels were allowed to equilibrate for 1 hour. After equil-
ibration, the arteries were constricted using a high potas-
sium solution (120mMKCl) and allowed to re-equilibrate.
This represented the maximal contractile force for the
artery (F-max). The baths were then emptied, and seg-
ments were rinsed three times with the Krebs-Henseleit
solution and again allowed to equilibrate.
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75% of F-max with 106M norepinephrine (Sigma). Ace-
tylcholine (Sigma) was then added in incremental log con-
centrations from 109M to 104M for determination of
EDR. Endothelial-independent relaxation (EIR) was mea-
sured in a similar fashion using sodium nitroprusside
(Sigma) from 109M to 107M. Baths were rinsed and
arterial segments brought to 75% F-max with norepineph-
rine between each reagent.
Nonspecific arginase blockadewas achievedby incubating
the aortic segments in difluoromethylornithine (DFMO).
Specific arginase blockade was accomplished using (S)-(2-
boronoethyl)-L-Cysteine-HCl (BEC). Incubation with BEC
or DFMO (Alexis Biochemicals, San Diego, Calif) occurred
for 1 hour during the equilibration period. Control vessels
underwent equilibrationwithKrebs-Henseleit physiologic so-
lution for 1 hour. For these experiments, a fixed norepineph-
rine dose of 106M was used to achieve contraction. EDR
and EIR were measured as above.
Experimental design. Normal, nonthrombosed aor-
tas (n  5) served as controls and were compared with
aortas (n  4) that underwent 1 hour of thrombosis. In
experiments using arginase inhibitors, nonthrombosed
control aortas (n  3) were compared with aortas after 1
hour of thrombosis (n 3) and thrombosed aortas treated
with the nonspecific arginase inhibitor DFMO (n  7) or
Fig 1. A, Thrombin-induced arginase I messenger RNA (mRNA)
expression in five separate experiments. B, Thrombin-induced argi-
nine I protein expression in three separate experiments. *P .001.the specific arginase inhibitor BEC (n  6).Statistical analysis. Data reported are mean  stan-
dard error of the mean. Single comparisons were made with
a two-tailed Student paired and unpaired t tests. Multiple
comparisons were made with two-way analysis of variance
(ANOVA), and the Bonferroni t test was used for post hoc
tests. Statistical significance was set at P  .05. Statistical
analysis was performed using Prism software (GraphPad,
San Diego, Calif).
RESULTS
Thrombin increases arginase I expression. Isolated
RAECs were exposed to thrombin, a major component of
arterial thrombus. Arginase I mRNA and protein expres-
sion were assayed after RAEC exposure to thrombin (30
U/mL) for 6 hours. RT-PCR results revealed a sevenfold
increase in arginase I message levels (6.76  1.4-fold, P 
.001, n  5) compared with controls (Fig 1, A) Immuno-
blot analyses was performed to study the effect of thrombin
on arginase I protein expression. Endothelial arginase I
protein levels increased 2.1 times with exposure to throm-
bin, confirmed on three separate Western blots (Fig 1, B).
Tubulin and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) levels both remained unchanged. Arginase I
protein levels also increased (1.5 times) with 1 hour and 4
hour exposure times to thrombin 30 U/mL. Lower levels
of thrombin exposure (10 U/mL) only showed minor
changes in arginase I protein levels. Arginase II was not
detectable in RAECs.
Endothelial-dependent relaxation is diminished by
arterial thrombosis. The effect of arterial thrombosis on
endothelial function was measured. After 60 minutes of
infrarenal aortic thrombosis, the aorta was harvested and
EDR and EIR were measured in an organ chamber system.
The nonthrombosed control rat aortas responded normally
Fig 2. Effect of thrombosis on endothelial-dependent relaxation
(EDR) of rat infrarenal aortic (IRA) ring segments. EDR is
plotted as percentage relaxation of baseline on the y axis, with log
increases in the dose of acetylcholine (Ach, 109M to 104M) on
the x axis. EDR of control (nonthrombosed) rat IRA (diamonds) is
compared with IRAs after 1 hour of thrombosis (squares). EDR is
depressed in the thrombosis group for all acetylcholine doses (n
5 in control and n 4 thrombosed group). *P .05, **P .001
by two-way analysis of variance. Data are presented with the
standard error.(Fig 2). EDR increased with increasing acetylcholine doses
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108% 4% of maximal EDR at acetylcholine 105M dose.
However, thrombosed rat aortic segments had significantly
lower EDR at all doses between acetylcholine 108M and
acetylcholine 105M and achieved amaximal EDRof 63%
6% (P  .001, two-way ANOVA). Arterial ring segments
responded uniformly to sodium nitroprusside with a 100%
EIR at the 107M doses of sodium nitroprusside. Of note,
all arterial ring segments constricted similarly with norepi-
nephrine and high potassium Krebs buffer.
Thrombosis increases arginase I protein expression.
Arginase protein expression was examined in infrarenal
aortic ring segments from nonthrombosed and throm-
bosed aortic segments (n 3). Thrombosed aortic segments
had higher (3.8-fold) arginase I protein expression compared
with control (Fig 3,A). Arginase II levelswere undetectable in
thrombosed as well as in control segments. To determine the
cellular source of arginase protein, we denuded the endothe-
lium from the aortic segments by gentle rubbing of the inner
surface. Arginase I levels were undetectable in these denuded
aortic segments (n  3), implying that the endothelium was
the source of arginase I (Fig 3, B).
Endothelial dysfunction is ameliorated by arginase
inhibitors. Because arginase protein expression was en-
Fig 3. A, Western blot analysis of arginase I (ARGI) in rat
infrarenal arterial segments. Arginase I protein levels were upregu-
lated in endothelium intact thrombosed infrarenal aortic ring
segments compared with control (n 3). B,Western blot analysis
of denuded aortic segments. Arginase I protein is not detected
(arrow indicates location of arginase I protein by size). GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.hanced by the exposure to thrombus, we explored theeffect of pharmacologic inhibitors of arginase on endothe-
lial function. A single, fixed dose of norepinephrine
(106M) was used to preconstrict infrarenal aortic seg-
ments in these experiments. The response of the control
and the thrombosed infrarenal aortic segments to norepi-
nephrine 106Mwas similar (1.0 0.7 g and 0.96 0.1 g,
respectively). However, maximum EDR was significantly
diminished (110%  8.2% vs 48%  7.3%, P  .001),
reconfirming the observation that the acute arterial throm-
bosis causes endothelial dysfunction. Incubation of throm-
bosed arterial rings using DFMO (107M), a nonspecific
arginase inhibitor, was performed for 1 hour. DFMO-
treated arterial rings (n  7) had significantly increased
EDR compared with untreated thrombosed infrarenal aor-
tic segments (maximum EDR, 104%  5.2% vs 53% 
7.0%, P  .001), as displayed in Fig 4.
We also tested the effects of a specific arginase blocker,
BEC, which has no effects on eNOS. Incubation of throm-
bosed aortic segments (n  6) with BEC (107M), also
significantly increased EDR compared with untreated
thrombosed infrarenal aortic segments (108%  7.6% vs
53% 7.0%, P .001, Fig 5). DFMO and BEC treatment
of thrombosed infrarenal aortic segments both led to nor-
malization of EDR with curves superimposed on the non-
thrombosed control curves. Vasoconstriction with norepi-
nephrine in all groups was similar (P  .5), indicating
uniform vasoconstricting capacity. The EIR, a measure of
smooth muscle function, was similar in control infrarenal
aortic segments, untreated thrombosed segments, and in
those incubated with either DFMOor BECwith increasing
Fig 4. Effect of nonspecific arginase inhibition on endothelial-
dependent relaxation (EDR) of thrombosed rat infrarenal aortic
(IRA) ring segments is shown. EDR is plotted as percentage
relaxation of baseline, with log increases in the dose of acetylcho-
line (Ach, 109M to 104M). EDR of nonthrombosed (control
IRA, diamonds; n  3) is compared with IRA segments after 1
hour of thrombosis untreated and treated with arginase inhibitors
(thrombosed IRA, clear squares; n 3) and treated with nonspecific
arginase inhibitor difluoromethylornithine (DFMO IRA, filled
squares; n  9). Treatment with arginase inhibitor restores the
EDR in thrombosed IRA. *P  .05, **P  .001 DFMO vs
thrombosed IRA; #P  .01, control vs thrombosed IRA by two-
way analysis of variance. Data are presented with the standard
error.doses of sodium nitroprusside, 109M to 107M (105%
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respectively, sodium nitroprusside 107M, P  NS).
DISCUSSION
The importance of an intact endothelium to balance
hemostasis, but prevent thrombosis, is well known. Although
most studies focus on the effect of endothelium on thrombus
generation, the effect of acute thrombosis on the vessel wall
remains under-appreciated. Endothelial dysfunction after
acute thrombosis has been observed inmultiple studies.6,10-12
Enhanced arginase activity has been implicated as a cause of
endothelial dysfunction in various disease models. In age-
related vascular dysfunction, Berkowitz et al2 showed that
older animals have increased arginase activity and expression
compared with younger animals. Inhibition of arginase phar-
macologically by using arginase inhibitors or by antisense
oligonucleotide restored the endothelial NO production. Ar-
ginase activity is increased in spontaneous as well as salt-
sensitive hypertensive rats.1,13 Arginase activity was associated
with increase in Rho A activity in atherosclerotic aortas in
apolipoprotein E/mice.3
For this study, we hypothesized that thrombin can lead
to increased arginase activity and that this may contribute
to the endothelial dysfunction in arteries exposed to acute
thrombus. We used cell culture of endothelial cells derived
from rat aortas to elucidate the mechanism of possible
impaired NO generation in endothelial cells. Based on our
work,12,14 and results from others,15 we evaluated the
response of RAECs to thrombin, a key enzyme of the
coagulation cascade and a potent component of arterial
thrombus. We found that thrombin increases the expres-
Fig 5. Effect of specific arginase inhibition on endothelial-
dependent relaxation (EDR) of thrombosed infrarenal aorta
(IRA) is shown. EDR plotted as percentage relaxation of baseline,
with log increases from 109M to 104M in the dose of acetyl-
choline (Ach). EDR of nonthrombosed (control IRA, triangle;
n 3) is compared with IRA after 1 hour of thrombosis untreated
with arginase inhibitors (Thrombosed IRA, clear square; n 3) and
treated with the specific arginase inhibitor [S]-[2-boronoethyl]-L-
Cysteine-HCl (BEC IRA, black square; n  6). Treatment with
arginase inhibitor restores the EDR in thrombosed IRA. **P 
.001 BEC vs thrombosed IRA analysis of variance. #P  .01,
##P  .001 control vs thrombosed IRA by two-way analysis of
variance. Data are presented with the standard error.sion of arginase mRNA determined by RT-PCR by nearlysevenfold. This results in more than a twofold increase in
arginase I protein concentration by Western blot analysis.
This is consistent with other reports in aging rats4 and
hypertensive rats,1,13 where enhanced arginase activity was
found along with increased arginase protein concentration,
which was responsible for the endothelial dysfunction.
Thrombin regulation of arginase protein could be oc-
curring at multiple levels, including translational as well as
post-translational levels. At the translational level, increased
message and its translation can lead to increased protein
concentrations in endothelial cells exposed to thrombus.
Ryoo et al16 found oxidized low-density lipoprotein causes
an increase in the arginase message as well as protein levels
in human aortic endothelial cells. Post-translational modi-
fication leading to release of arginase from cellular storage
could be another possibility if microtubules served as stor-
age for arginase. Recently, other investigators found that
human umbilical vein endothelial cells exposed to throm-
bin (25nM) for 10minutes caused destabilization of 44% of
tubulins.17 Destabilization of the microtubule architecture
by depolymerization can lead to decreases in NO genera-
tion.18 Arginase II, the predominant isoform in human
endothelial cells, colocalizes with tubulins in human aortic
cells experiments. This intriguing mechanism could par-
tially explain the increase in arginase protein levels observed
after 1 hour of acute arterial thrombosis.
The results of the endothelial function studies using
arterial ring samples are compelling. Endothelial function
(EDR) diminished with thrombosis. All the vessels retained
the capacity to dilate to the NO donor sodium nitroprus-
side, indicating normal smooth muscle cell responsiveness
to NO. Furthermore, arginase I protein levels were in-
creased in the thrombosed specimens. Denudation of the
endothelial layer in the thrombosed as well as in control rat
infrarenal arteries made arginase undetectable in these ves-
sels, confirming the tissue source as endothelial cell layer.
This is consistent with the White et al4 finding of arginase I
to be present predominately in the endothelial layer in rat
artery. In contrast, Zhang et al19 reported the presence of
arginase in endothelial as well as smooth muscle layers of
the porcine coronary artery. Buga et al20 has showed argi-
nase I and II both to be present in rat aorta and found
arginase I to be constitutively expressed, whereas arginase
II was induced by lipo polysaccharide.
Distribution of isomers of arginase enzyme in vascular
tissue appears to be species specific. In porcine artery and
rat aorta, arginase I is predominant and constitutively ac-
tive,19,20 whereas arginase II is found in mouse aorta.3
Both isomers are found in human umbilical vein endothe-
lial cells.14,21 Of note, previous experiments on arginase
isoforms may have been complicated by smooth muscle
contamination of endothelial specimens.
The use of the arginase inhibitors DFMO and BEC
restored endothelial function in arteries exposed to throm-
bosis. DFMO is a nonspecific but efficient arginase inhibi-
tor as well as an inhibitor of ornithine decarboxylase, the
rate-limiting enzyme for polyamine synthesis from orni-
thine. Because DFMO also is an inhibitor of ornithine
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urea cycle can interfere in NO production, we repeated
these experiments with BEC, a boric acid analogue of
L-arginine and a specific arginase inhibitor. BEC is a
potent arginase inhibitor and has no effect on eNOS
function. These data indicate that DFMO and BEC
through inhibition of arginase can restore endothelial
function in thrombosed aortic rings, perhaps by increas-
ing NO bioavailability.
This work has several limitations. Other factors in
thrombus may be playing a role in endothelial dysfunction.
We chose to study thrombin and its relationship to argi-
nase, but thrombosis involves multiple mechanisms. Our
model of acute thrombosis is not ideally designed to study
the inflammatory component of the thrombosis cascade.
Lipo polysaccharide–activated endothelial cells induce a
different arginase isoform, inducible NOS upregulation,
and relatively large increases in NO production with native
arginase suppression, which maybe more relevant to in-
flammation.20 The question remains of whether throm-
bin’s effects are receptor-dependent or through a global,
nonspecific effect. We chose to use a single dose of throm-
bin based on previous studies.14,22
Additional mechanistic studies are needed and are cur-
rently underway, including the effects of thrombin on the
arginase promoter complex and examining L-argininemetab-
olites. The relevanceof these findings to the clinical scenario of
thrombosis in diseased arteries and endothelium is unknown.
Presumably, the younger patient with an embolus causing
acute ischemia in otherwise normal arteries would be the
closest clinical correlate. Human clinical studies in this arena
would be compelling. Finally, the role of arginase inhibitors as
a clinical adjunct remains unknown.
CONCLUSIONS
This study shows that thrombin increases arginase protein
and message levels in endothelial cells. Similarly, thrombosed
rat aortas develop endothelial dysfunction, increase arginase
protein levels, and restore endothelial function with arginase
inhibitors. Further research in this area is warranted.
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